HURA
TuHURA Biosciences, Inc./NV
NASDAQ · Healthcare · Biotechnology · US
$1.78
+1.14%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.75
From 52W high−43.49%
Volume173408.00
Market cap$113.43M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.75
From 52W high
−43.49%
Volume
173408.00
Market cap
$113.43M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
P/E (TTM)
—
RSI (14)
38.1
MomentumView details →
1D Return
+1.14%
YTD Return
+136.55%
SummaryUpdated Jun 1, 2026
TuHURA Biosciences, Inc. (NASDAQ:HURA) is a clinical-stage biotechnology company founded in 2013 and headquartered in Tampa, Florida. The company focuses on developing novel immuno-oncology therapies designed to overcome resistance mechanisms that limit the effectiveness of current cancer immunotherapies. TuHURA has progressed to phase 3 registration-stage trials, representing a significant milestone in bringing potentially life-saving cancer treatments to market.
Similar companies
Latest newsMore news →
The U.S. Patent and Trademark Office issued TuHURA Biosciences a patent broadening coverage for its VISTA inhibitor TBS-2025 to include bispecific and multispecific antibodies across all classes of human antibodies.6d agoThe U.S. FDA granted TuHURA Biosciences IND clearance and a "Study May Proceed" notice for its TBS-2025 VISTA-inhibiting antibody in molecularly defined subsets of AML and other blood-related cancers.35d agoParabilis Medicines, Inc. appointed Craig Tendler, M.D., as a director, effective August 22, 2026, and granted him a stock option to purchase 20,294 shares of common stock at an exercise price of $39.36 per share.56d ago